BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables)

12 Months Ended

Sep. 30, 2023

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES

Schedule of revenues disaggregated by business operations and timing of revenue recognition

	Fiscal Years Ended:
	September 30,
	2023		2022
Research and development services (over-time)	$	421,585	$	592,001
Clinical laboratory testing services (point-in-time)		7,612,975		10,398,782
Clinical laboratory services (over-time)		3,540,456		5,127,953
Product and authentication services (point-in-time):
Supply chain		827,603		887,061
Large Scale DNA Production		653,015		—
Asset marking		311,809		534,594
MDx test kits and supplies		—		628,286
Total	$	13,367,443	$	18,168,677

Schedule of opening and closing contract balances

		October 1,		September 30,		$
	Balance sheet classification	2022		2023		change
Contract liabilities	Deferred revenue	$	563,557	$	270,435	$	293,122

		October 1,		September 30,		$
	Balance sheet classification	2021		2022		change
Contract liabilities	Deferred revenue	$	281,000	$	563,557	$	(282,557)

Schedule of anti-dilutive securities not included computation of net loss per share

	2023	2022
Warrants	5,220,588	7,313,963
Restricted Stock Units	282,640	—
Options	2,204,237	1,063,055
	7,707,465	8,377,018

Schedule of reconciliation of cash, cash equivalents and restricted cash to amounts shown in statement of cash flows

	September 30,		September 30,
	2023		2022
Cash and cash equivalents	$	7,151,800	$	15,215,285
Restricted cash		750,000		—
Total cash, cash equivalents and restricted cash	$	7,901,800	$	15,215,285

Schedule of property, plant and equipment

	September 30,
	2023		2022
Lab equipment	$	4,069,175	$	4,059,754
Vehicles		56,471		108,361
Leasehold improvements		124,825		124,825
Total		4,250,471		4,292,940
Accumulated depreciation		3,412,201		2,069,952
Property and equipment, net	$	838,270	$	2,222,988